Amneal Pharma starts commercial operations in India

October 11, 2022 09:47 pm | Updated 09:47 pm IST - Mumbai

Amneal Pharmaceuticals, an NYSE listed company, said it had started commercial operations in India. Shyamakant Giri has been appointed as the managing director and president, India Business and Emerging Markets. 

In his new role, Mr. Giri will be responsible for Amneal’s commercial expansion and growth in India, Africa, Gulf, CIS and South Asian markets.

The company has manufacturing and R&D footprint in India since 2008 with a focus on exports of key molecules and products from its facilities across Ahmedabad, Dahej, Hyderabad and Vizag.

With the commencement of commercial operations in India, it plans to provide products at affordable prices.

Chirag and Chintu Patel, co-chief executive officers, Amneal said,  “We look forward to working with the Indian stakeholders to make healthy possible through increased access to the latest innovations in essential medicines.”

“Being a community-oriented firm, we have placed a specific emphasis on innovating products that address the market’s unmet needs. On boarding an industry veteran like Giri, who shares our vision, will be a major impetus behind our growth in India,” they added.

Top News Today


Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.

We have migrated to a new commenting platform. If you are already a registered user of The Hindu and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.